Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dr Bruce Chabner joins Peregrine as clinical advisor

This article was originally published in Scrip

Executive Summary

Peregrine Pharmaceuticals (US) has elected cancer researcher Dr Bruce Chabner as a clinical advisor on the design of clinical trials for its bavituximab cancer programme. Dr Chabner is clinical director of the Massachusetts General Hospital (MGH) Cancer Center, chief of haematology and oncology at MGH and a professor of medicine at Harvard Medical School. Before that, he had a 25-year career at the National Cancer Institute, including serving as scientific director and director of the division of cancer treatment.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts